NCT07029503 2026-02-24
SCARF-1
Karolinska Institutet
Phase 2 Recruiting
Clinical Trials
10 trialsNCT04240054 2026-01-28
VICD
Medical College of Wisconsin
Phase 2 Recruiting
NCT04352205 2024-07-01
Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure
Emory University
Phase 2 Terminated
NCT05147493 2022-03-29
A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment
Hellenic Society of Hematology
Phase 2 Unknown
NCT05298683 2022-03-28
A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor
Hellenic Society of Hematology
Phase 2 Unknown
NCT02424851 2022-01-27
OPTIMAL
Oxford University Hospitals NHS Trust
Phase 2 Completed
NCT01270932 2017-12-29
Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure Patients
University Health Network, Toronto
Phase 2 Completed
NCT00779922 2016-10-11
Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function
Poitiers University Hospital
Phase 2 Completed
NCT01084837 2015-09-17
RENVEL
PETHEMA Foundation
Phase 2 Completed
NCT00401804 2013-01-24
Bortezomib-Dexamethasone-Doxorubicin-Study
Austrian Forum Against Cancer
Phase 2 Completed